As per the research report, the size of the Europe Rubella Vaccine (Human Diploid Cell) market was valued at USD XX Billion in 2023 and is expected to reach USD XX Billion by 2028 at XX % CAGR during the forecast period 2023 to 2028.
The increased investment in the development of new vaccines against rubella infection is predicted to boost the European rubella vaccine market in the coming years. In addition, the increasing incidence of various air-borne infectious diseases and the growing awareness of rubella and disease prevention are driving the demand for rubella vaccines.
Vaccination helps prevent nearly 2 to 3.5 million deaths from various diseases, such as influenza, rubella, tetanus, diphtheria, measles, pertussis and others. In addition, according to the WHO, more than 1.55 million deaths can be prevented by improving immunization coverage. In 2019, approximately 116.38 million children under one year of age received doses of MMR vaccine worldwide. It has been reported that susceptibility rates are high for serological tests, both in the general population and in childbearing age women. With the increase in vaccine administration in infants, children and pregnant women will expand the market considerably in the years to come.
Various efforts by organizations, including UNICEF, PAHO, have increased vaccine uptake over the years. These agencies allow the purchase of vaccines at lower prices for several countries. Each year, PAHO and UNICEF purchase vaccines for nearly 40 states and about 100 countries, which has a positive impact on the adoption rate. The rubella vaccine coverage has reduced the disease rate but not completely eradicated the circulation of the rubella virus and, as a result, more cases of congenital rubella are seen in Italy.
On the contrary, factors such as strict government regulations for vaccine approval, delayed products launches and certain side-effects associated with vaccines affect the European rubella vaccine market. This is considered to restrain the growth of the market.
This research report on the Europe Rubella Vaccine Market has been segmented and sub-segmented into the following categories:
By End User:
By Country:
Geographically, the U.K Rubella Vaccine Market accounted for the majority of the Europe rubella vaccine market in 2022. This regional market growth can be attributed to the high prevalence of rubella, large population and increased investments by government and non-government organizations for research and development. A total of 58 cases of rubella were reported for 2019. This figure translates into an incidence of 0.78 per million inhabitants. The number of rubella cases decreased between 2013 and 2018 and appears to be at a constant level with around 50-60 cases since 2018.
The Italy Rubella Vaccine Market is anticipated to show the highest growth during the estimated period. Factors such as increase in healthcare expenditure and high disposable income, supportive government initiatives and presence of product availability are driving the growth of the market in Italy. Rubella continues to circulate in Italy, in 1996 the percentage of women susceptible to rubella between 15-39 years old was above 5%. Congenital rubella syndrome is a critical condition seen in pregnant ladies affecting 8 to 76 cases reported each year.
The impact of rubella vaccination in Italy can be calculated by monitoring disease incidence and susceptibility level. Campaigns by the Disease incidence surveillance systems in Italy like the National Disease Notification Program and the Pediatric Sentinel Surveillance Network (SPES) have helped reduce the rubella infection rate, coupled with R&D to reduce the number of side-effects. The market will have steady growth rate, which will subsequently result in expansion of the Europe rubella vaccine market in the years to come.
KEY MARKET PLAYERS
Key players operating in the European Rubella Vaccine Market profiled in this report are Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotech (Crucell).,
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region